Alutard SQ Wasp Venom: Uses, Dosage & Side Effects

What Is Alutard SQ Wasp Venom and What Is It Used For?

Alutard SQ Wasp Venom belongs to the class of allergen immunotherapy (AIT) products, specifically subcutaneous immunotherapy (SCIT) preparations. It is manufactured by ALK-Abelló A/S, a Danish pharmaceutical company that specialises in allergy treatments. The product contains a standardised allergen extract from the venom of several Vespula wasp species, including Vespula germanica (European wasp), Vespula alascensis, Vespula maculifrons, Vespula flavopilosa, Vespula pensylvanica, and Vespula squamosa. The allergen extract is adsorbed onto aluminium hydroxide as an adjuvant, which provides a depot effect and enhances the immunological response.

The product is approved in numerous European countries and is marketed under various names across the European Economic Area, including Alutard SQ Wasp (United Kingdom, Belgium, Ireland, Luxembourg), Alutard SQ Wespengift (Austria), and Alutard SQ Vespula spp. (Portugal, Spain). It is indicated for use in patients who have experienced severe systemic allergic reactions — classified as Grade III or IV according to the Müller classification — following wasp stings. These reactions include generalised urticaria, angioedema, bronchospasm, hypotension, and anaphylactic shock.

The purpose of allergen immunotherapy with Alutard SQ is to address the underlying cause of wasp venom allergy rather than merely treating symptoms. By exposing the immune system to gradually increasing doses of purified wasp venom allergen, the treatment induces a state of immune tolerance. This is achieved through several complementary immunological mechanisms: the generation of allergen-specific blocking antibodies (primarily IgG4), suppression of allergen-specific IgE production, induction and expansion of regulatory T-cells (Tregs), and modulation of mast cell and basophil degranulation thresholds. Together, these changes reduce the likelihood and severity of allergic reactions upon subsequent exposure to wasp stings.

Clinical evidence strongly supports the efficacy of venom immunotherapy. Systematic reviews published in the Cochrane Database of Systematic Reviews, along with randomised controlled trials, have consistently demonstrated that venom immunotherapy provides 90 to 95% protection against systemic allergic reactions to wasp stings. The EAACI (European Academy of Allergy and Clinical Immunology) 2023 guidelines on allergen immunotherapy for Hymenoptera venom allergy recommend SCIT as the standard of care for patients with a history of severe systemic reactions and confirmed venom sensitisation by skin prick testing or specific IgE measurement.

Who Should Receive Alutard SQ Wasp Venom?

Alutard SQ Wasp Venom is recommended for adults and children from 5 years of age who have experienced severe systemic allergic reactions following wasp stings and who have confirmed IgE-mediated sensitisation to wasp venom. The decision to initiate venom immunotherapy should be made by an allergist or immunologist following a thorough clinical evaluation, including a detailed history of the index sting reaction, skin prick testing with wasp venom extracts, and/or measurement of serum-specific IgE antibodies to wasp venom components.

According to EAACI guidelines, venom immunotherapy is particularly recommended for patients who have experienced Grade III or Grade IV systemic reactions (involving respiratory distress, cardiovascular collapse, or loss of consciousness) and who have an elevated serum tryptase level or mastocytosis, as these patients carry the highest risk of fatal anaphylaxis from subsequent stings. The treatment may also be considered for patients with Grade II systemic reactions (generalised urticaria, angioedema) who have significant risk factors such as frequent exposure to wasp stings (e.g., beekeepers, outdoor workers) or substantial impairment of quality of life due to anxiety about future stings.

What Should You Know Before Receiving Alutard SQ Wasp Venom?

Contraindications

Alutard SQ Wasp Venom must not be used in patients who are allergic to any of the excipients (inactive ingredients) in the formulation, which include aluminium hydroxide (hydrated), sodium chloride, sodium hydrogen carbonate, phenol, sodium hydroxide, and water for injections. While hypersensitivity to these excipients is rare, it should be confirmed before initiating treatment.

The treatment is contraindicated in patients with diseases affecting the immune system, including primary immunodeficiency disorders, severe combined immunodeficiency (SCID), and acquired immunodeficiency conditions. Patients receiving potent immunosuppressive therapy (such as high-dose systemic corticosteroids, biological immunomodulators, or chemotherapy) should also not receive allergen immunotherapy, as the immune modulation required for successful treatment cannot be achieved in the context of significant immunosuppression.

Patients who have recently experienced an asthma exacerbation — including increased daytime symptoms, nocturnal awakenings due to asthma, increased use of rescue inhalers, or limitation of physical activities — must not receive Alutard SQ until their asthma is well controlled. Uncontrolled asthma is a significant risk factor for severe or fatal anaphylaxis during allergen immunotherapy. Forced expiratory volume in one second (FEV1) should ideally be above 70% of predicted before each injection.

Severe cardiovascular disease is a further contraindication. Patients with unstable angina, recent myocardial infarction, severe heart failure (NYHA class III–IV), or poorly controlled hypertension should not receive allergen immunotherapy due to the risk of haemodynamic compromise during anaphylaxis and the potentially impaired response to adrenaline (epinephrine) treatment.

Warnings and Precautions

Before each injection, the treating physician or nurse should assess the patient for any changes in health status since the previous dose. It is essential to inform the healthcare provider if you experienced any adverse reactions after the previous injection, as this may require dose adjustment. The injection site reaction from the previous dose should be evaluated; if a local reaction persisted for more than six hours after injection, the physician may need to reduce the dose.

Patients with chronic heart disease should be treated with particular caution, as cardiovascular events during anaphylaxis can be more severe and harder to manage in these individuals. Patients with impaired renal function should inform their physician, as there may be a risk of aluminium accumulation from the aluminium hydroxide adjuvant present in the formulation, particularly with long-term treatment over several years.

Patients with autoimmune diseases, malignancies, or elevated serum tryptase levels should discuss the risks and benefits of treatment with their allergist. Mastocytosis or other conditions associated with an elevated number of mast cells in the body are associated with an increased risk of severe anaphylaxis during both natural wasp stings and immunotherapy. However, these patients also have the greatest clinical need for venom immunotherapy, and international guidelines recommend treatment with additional precautions.

If you have active symptoms of hay fever or other allergic rhinitis within the 3 to 4 days preceding your scheduled injection, or if you have a flare-up of eczema, inform your physician. These conditions may indicate heightened immune reactivity and could increase the risk of a systemic reaction to the injection. Similarly, any signs of fever or infection on the day of the scheduled injection should be reported, and the injection may need to be postponed.

Children and Adolescents

For children aged 5 years and older, limited data are available on clinical efficacy. However, safety data have not demonstrated a higher risk in children compared to adults. The decision to initiate venom immunotherapy in children should be made on an individual basis by the treating allergist, weighing the severity of the initial allergic reaction, the risk of future exposure to wasp stings, and the potential benefits of treatment against the burden of a multi-year injection regimen. For children under 5 years of age, the treating physician should carefully evaluate the individual risks and benefits before initiating treatment.

Pregnancy and Breastfeeding

The updosing phase of Alutard SQ Wasp Venom must not be initiated during pregnancy due to the risk of systemic allergic reactions (including anaphylaxis) that could compromise both the mother and the foetus. However, if a patient becomes pregnant during ongoing maintenance treatment, the treating physician should carefully evaluate the risks and benefits of continuing therapy. In many cases, if the patient has been tolerating the maintenance dose well without significant adverse reactions, treatment may be continued with appropriate monitoring.

It is not known whether the allergen components of Alutard SQ pass into breast milk. Breastfeeding mothers should consult their allergist before starting or continuing treatment. The potential risk to the nursing infant must be weighed against the clinical benefit of continued venom immunotherapy for the mother, particularly in cases where the risk of severe anaphylaxis from a wasp sting is considered significant.

Driving and Operating Machinery

Alutard SQ Wasp Venom may affect the ability to drive or operate machinery in some patients, as dizziness is a potential side effect that can occur after each injection. Patients should assess their own condition before driving, particularly in the hours following an injection. The mandatory 30-minute observation period after each injection provides an opportunity for the initial assessment of any post-injection symptoms, but patients should remain vigilant for delayed reactions that may occur up to 24 hours after the injection.

How Does Alutard SQ Wasp Venom Interact with Other Drugs?

Drug interactions with Alutard SQ Wasp Venom are clinically important because they primarily affect the risk and management of anaphylaxis, the most serious potential complication of allergen immunotherapy. Unlike many conventional medications that interact at the pharmacokinetic level (absorption, distribution, metabolism, excretion), the interactions relevant to Alutard SQ are primarily pharmacodynamic — they alter the body's ability to respond to or treat anaphylaxis, rather than changing drug concentrations.

It is essential to inform your allergist about all medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and any recent vaccinations. Your physician will evaluate the overall risk-benefit balance and may adjust the immunotherapy protocol or recommend alternative management of your concomitant conditions.

Beta-blockers and ACE Inhibitors

Beta-blockers represent the most clinically significant drug interaction with Alutard SQ Wasp Venom. These medications block beta-adrenergic receptors, which are the primary targets of adrenaline (epinephrine), the first-line treatment for anaphylaxis. In a patient taking beta-blockers who develops anaphylaxis during immunotherapy, adrenaline may be significantly less effective at reversing bronchospasm, hypotension, and tachycardia. Furthermore, beta-blockers can lower the threshold for anaphylaxis and increase the severity of anaphylactic episodes. International guidelines recommend that patients on beta-blockers should be switched to alternative antihypertensive medications before starting venom immunotherapy, where medically appropriate.

ACE inhibitors (angiotensin-converting enzyme inhibitors) have been associated with an increased risk of anaphylactic reactions during allergen immunotherapy. ACE is involved in the degradation of bradykinin, a potent vasodilator. By inhibiting ACE, these medications lead to increased bradykinin levels, which may amplify the hypotensive response during anaphylaxis. Some allergists recommend switching patients from ACE inhibitors to angiotensin receptor blockers (ARBs) before initiating venom immunotherapy, as ARBs have not been associated with the same increased risk.

Concurrent Allergy Medications

Patients taking other allergy medications, such as antihistamines or corticosteroids, should inform their treating physician. These medications may increase the patient's tolerance to allergen injections by suppressing the immediate allergic response, which can have both beneficial and potentially misleading effects. While premedication with antihistamines is sometimes used deliberately by the treating physician to reduce local and systemic reactions, it is important that the physician is aware of all concurrent allergy medications to correctly interpret the patient's response to treatment and adjust doses appropriately.

What Is the Correct Dosage of Alutard SQ Wasp Venom?

Alutard SQ Wasp Venom is always administered as a subcutaneous injection by a physician or nurse experienced in specific immunotherapy. The injection is given in the lateral aspect of the upper arm (distal) or the dorsal aspect of the proximal forearm. Intravascular injection must be carefully avoided by aspiration before injection, with aspiration repeated for every 0.2 mL during the injection. The injection must be administered slowly to minimise the risk of systemic reactions.

Full anaphylaxis preparedness must be available at all times during treatment with Alutard SQ. This includes adrenaline (epinephrine), antihistamines, corticosteroids, intravenous fluid replacement, oxygen, and equipment for airway management. The patient must remain under medical observation for at least 30 minutes after each injection to allow detection and immediate treatment of any systemic allergic reaction.

Updosing Phase

The updosing phase is the initial treatment period during which the dose of wasp venom allergen is gradually increased from a very low starting level to the maximum tolerated dose or the maximum recommended maintenance dose. The treatment is initiated according to a dosing schedule determined by the treating physician, tailored to the individual patient's sensitivity and tolerance. Injections during this phase are typically given once per week.

The product is supplied in a strength series of four vials with colour-coded caps to distinguish the different concentrations:

The updosing phase typically takes between 7 and 25 weeks, depending on the individual patient's tolerance and the specific dosing protocol used by the treating centre. The physician will gradually increase the injected volume and concentration of allergen over successive visits. If a significant local reaction persists for more than six hours after an injection, the physician will evaluate the reaction and may adjust subsequent doses based on the size and duration of the skin reaction. The physician may also prescribe an antihistamine to be taken before the injection to reduce local reactions.

Maintenance Phase

Once the maximum tolerated dose or the maximum recommended dose has been reached, the patient transitions to the maintenance phase. During this phase, the interval between injections is gradually extended. The standard maintenance schedule involves injections every 6 to 8 weeks. Treatment during the maintenance phase continues for a total of 3 to 5 years to achieve optimal and lasting immune tolerance.

The duration of maintenance treatment is important for long-term outcomes. Studies have shown that patients who complete 3 to 5 years of maintenance venom immunotherapy maintain significant protection even after treatment discontinuation. The EAACI 2023 guidelines recommend a minimum of 3 years of maintenance treatment for most patients, with longer treatment periods (5 years) recommended for patients with elevated serum tryptase, mastocytosis, or a history of very severe anaphylaxis.

Concurrent Treatment with Multiple Allergens

If a patient is undergoing simultaneous immunotherapy with multiple allergens (for example, both wasp venom and bee venom), the injections for different allergens should be given at least 30 minutes apart. This separation allows for observation after each injection and helps distinguish between allergen-specific reactions. The injections should be administered in different limbs where possible.

Missed Dose

If the interval between injections exceeds the recommended schedule, the treating physician will reduce the dose to minimise the risk of an allergic reaction. The degree of dose reduction depends on the length of the delay. A longer-than-planned interval may mean that some of the immune tolerance achieved during the previous injections has diminished, and a lower dose is needed to safely resume treatment. Patients should contact their allergy clinic promptly if they need to reschedule or miss an injection to receive guidance on dose adjustment.

Overdose

As Alutard SQ is administered exclusively by healthcare professionals in a clinical setting, overdose is extremely unlikely. However, if an excessive dose is inadvertently administered, the patient will be monitored closely for signs of a systemic allergic reaction. Full emergency treatment facilities, including adrenaline, antihistamines, corticosteroids, and equipment for managing anaphylaxis, are always available during treatment sessions.

What Are the Side Effects of Alutard SQ Wasp Venom?

Like all allergen immunotherapy products, Alutard SQ Wasp Venom can cause side effects, although not every patient will experience them. The side effects are a consequence of the immune response to the injected wasp venom allergen — the same allergen that causes the patient's allergy. Local reactions at the injection site are the most common side effects and are generally considered a normal part of the treatment process. Systemic reactions, while less frequent, require careful monitoring and may necessitate dose adjustment or additional treatment.

Side effects typically appear within 30 minutes of the injection, which is why the mandatory observation period is essential. However, delayed reactions can occur up to 24 hours after the injection. Patients should be aware of potential symptoms and seek medical attention if they experience any concerning reactions after leaving the clinic.

Anaphylaxis

Anaphylaxis is the most serious potential side effect of Alutard SQ Wasp Venom. Although it occurs in a small proportion of patients, it is a medical emergency that requires immediate treatment. Anaphylaxis can manifest as a rapid onset of generalised urticaria, angioedema (swelling of the face, lips, tongue, or throat), bronchospasm (causing difficulty breathing and wheezing), hypotension (low blood pressure causing dizziness or loss of consciousness), gastrointestinal symptoms (nausea, vomiting, diarrhoea), and cardiovascular collapse.

The risk of anaphylaxis is highest during the updosing phase when the allergen dose is being increased. Risk factors include a history of previous severe systemic reactions to immunotherapy injections, elevated baseline serum tryptase, mastocytosis, uncontrolled asthma, and concurrent use of beta-blockers or ACE inhibitors. The mandatory 30-minute observation period after each injection, combined with the availability of full anaphylaxis treatment equipment, is designed to ensure that anaphylaxis can be detected and treated promptly if it occurs.

Managing Local Reactions

Local injection site reactions are the most commonly observed side effects and usually do not require specific treatment. Mild to moderate swelling, redness, and itching at the injection site can typically be managed with cold compresses and, if needed, an oral antihistamine. If a local reaction is larger than expected or persists for more than six hours, the treating physician should be informed, as dose adjustment for the subsequent injection may be necessary.

Reporting Side Effects

It is important to report suspected side effects to your healthcare provider and to the relevant national pharmacovigilance authority. In the United Kingdom, adverse reactions can be reported through the MHRA Yellow Card Scheme. In the European Union, reports can be made to the national competent authority in each member state. In the United States, reports can be filed with the FDA through the MedWatch programme. Reporting side effects helps regulatory agencies continuously monitor the benefit-risk balance of medicines and improve patient safety.

How Should Alutard SQ Wasp Venom Be Stored?

Alutard SQ Wasp Venom must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F to 46°F). The product must not be frozen, as freezing can damage the aluminium hydroxide adjuvant matrix and compromise the quality and consistency of the allergen suspension. The vials should be kept in their original packaging to protect the product from light, as the allergen extract is light-sensitive.

Once opened, each vial has a shelf life of 6 months when used for a single patient and stored correctly in the refrigerator. The expiry date printed on the label (after "EXP") refers to the last day of the indicated month. Do not use the product after this date. Before administration, the suspension should be gently inverted 10 to 20 times to ensure a homogeneous mixture, as sedimentation can occur during storage. The sediment may appear white to slightly brown or green, which is normal for this type of suspension.

Before each use, the healthcare professional should visually inspect the suspension for particulate matter. If visible particles are present that do not disperse upon gentle inversion, the product should be discarded. The vials must be kept out of the sight and reach of children. Unused or expired product should be disposed of according to local regulations for pharmaceutical waste — it should not be disposed of via household waste or flushed down drains.

What Does Alutard SQ Wasp Venom Contain?

Active Ingredient

The active substance is allergen from wasp venom (Vespula spp.). The extract is derived from the venom of six Vespula species: Vespula germanica (European wasp, also known as the German yellowjacket), Vespula alascensis, Vespula maculifrons (Eastern yellowjacket), Vespula flavopilosa, Vespula pensylvanica (Western yellowjacket), and Vespula squamosa (Southern yellowjacket). The inclusion of multiple Vespula species provides broad cross-reactivity and ensures that the treatment is effective against stings from the most common wasp species encountered across Europe and North America.

The allergen extract is standardised in Standardised Quality units (SQ-E/mL), a proprietary unit developed by ALK-Abelló to ensure batch-to-batch consistency in allergen content and biological potency. The allergen is adsorbed onto aluminium hydroxide (hydrated), which serves as an adjuvant to enhance the immunological response and provide a depot effect, allowing for slower allergen release from the injection site.

Inactive Ingredients (Excipients)

• Aluminium hydroxide (hydrated) — adjuvant that enhances immune response and provides depot effect; content ranges from 0.00113 mg/mL (Vial 1) to 1.13 mg/mL (Vial 4)
• Sodium chloride — provides isotonicity to the injection solution
• Sodium hydrogen carbonate — pH buffer
• Phenol — preservative
• Sodium hydroxide — pH adjustment
• Water for injections — solvent

Sodium Content

Alutard SQ Wasp Venom contains less than 1 mmol sodium (23 mg) per dose, which means it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.

Appearance and Packaging

Alutard SQ Wasp Venom is a suspension for injection. The suspension is white to slightly brown or green in colour. During storage, a sediment and a clear supernatant may be observed, which is normal for an aluminium hydroxide-adsorbed suspension and does not indicate deterioration of product quality. The product is available in two packaging configurations: a strength series containing four vials (with grey, green, orange, and red colour-coded caps) for the updosing phase, and a single-vial maintenance pack containing the highest concentration (100,000 SQ-E/mL) with a red cap.

References

This article is based on the following international medical guidelines, regulatory documents, and peer-reviewed sources:

1. European Medicines Agency (EMA). Summary of Product Characteristics — Alutard SQ Wasp Venom (Vespula spp.). Updated 2024. Available from: www.ema.europa.eu
2. Sturm GJ, et al. EAACI Guidelines on Allergen Immunotherapy: Hymenoptera venom allergy. Allergy. 2023;78(2):369-420. doi:10.1111/all.15494
3. Dhami S, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database of Systematic Reviews. 2023;(10):CD008838. doi:10.1002/14651858.CD008838.pub3
4. Cardona V, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472
5. World Health Organization (WHO). WHO Position Paper on Allergen Immunotherapy. Geneva: World Health Organization; 2022.
6. Golden DBK, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28-54. doi:10.1016/j.anai.2016.10.031
7. Bonadonna P, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2023;11(2):392-401.
8. Rueff F, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase — a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124(5):1047-1054.
9. Bilò MB, et al. Diagnosis of Hymenoptera venom allergy. Allergy. 2005;60(11):1339-1349.
10. British National Formulary (BNF). Hymenoptera venom immunotherapy. National Institute for Health and Care Excellence (NICE). Available from: bnf.nice.org.uk

Editorial Team

Last medical review: February 4, 2026 | Next scheduled review: August 2026